Trianni and Juno Therapeutics Sign Licensing Agreement for Use of Trianni Transgenic Mouse Platform

SAN FRANCISCO, Oct. 18, 2017 /PRNewswire/ -- Trianni, Inc. ("TRIANNI") today announced that Juno Therapeutics (NASDAQ: JUNO) has entered into a license agreement for The Trianni Mouse™, a best-­in-class monoclonal antibody discovery platform. Juno intends to use The Trianni Mouse with its proprietary high throughput, single cell sequencing technology and direct-­to-­CAR screening to rapidly identify fully-human binders for conversion to chimeric antigen receptors in its engineered T cell programs.

"TRIANNI is pleased to bolster Juno's lead generation capabilities through a license to The Trianni Mouse," stated Dr. David Meininger, TRIANNI's Chief Business Officer. "We are confident that Juno's deep expertise in developing engineered T cells will potently synergize with the industry-leading human antibody repertoires provided by The Trianni Mouse."

"The Trianni Mouse offers an in vivo platform for generating a diverse human antibody response to tumor targets of interest," said Hy Levitsky, M.D., Juno's Chief Scientific Officer.

"We look forward to using the technology to advance our discovery efforts and build more effective, next-­generation CAR T cells."

No financial details were disclosed.

About Trianni, Inc.
Trianni, Inc. is a privately held biotech company specializing in antibody discovery technology. TRIANNI's lead technology, The Trianni Mouse™, is a powerful, next-­generation platform enabling efficient generation of fully-­ human monoclonal antibodies. TRIANNI's transgenic platform leverages a novel approach to design made possible by advances in DNA synthesis and genomic modification technology making it a best-­in-­class therapeutic antibody discovery platform. The company  is  headquartered  in  San  Francisco,  CA.  Additional information about TRIANNI is available through its corporate website, www.trianni.com.

Forward-Looking Statement
This press release contains "forward-­looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including statements regarding Juno's mission, progress, and business plans, and the potential of The Trianni Mouse to advance Juno's discovery efforts and build more effective, next-­generation CAR T cells. Forward-­looking statements are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, risks associated with: the success, cost, and timing of Juno's product development activities and clinical trials; Juno's ability to obtain regulatory approval for and to commercialize its product candidates; Juno's ability to establish a commercially-­viable manufacturing process and manufacturing infrastructure; regulatory requirements and regulatory developments; success of Juno's competitors with respect to competing treatments and technologies; Juno's dependence on third-­party collaborators and other contractors in Juno's research and development activities, including for the conduct of clinical trials and the manufacture of Juno's product candidates; Juno's ability to attract and retain key scientific, quality control/assurance, manufacturing or management personnel; Juno's dependence on Celgene for the development and commercialization outside of North America and China of Juno's CD19 product candidates and any other product candidates for which Celgene exercises an option; Juno's dependence on JW Therapeutics (Shanghai) Co., Ltd, over which Juno does not exercise complete control, for the development and commercialization of product candidates in China; Juno's ability to obtain, maintain, or protect intellectual property rights related to its product candidates; amongst others. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-­looking statements, as well as risks relating to Juno's business in general, see the information Juno has included it its periodic reports and other documents filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Juno disclaims any obligation to update these forward-looking statements.

Contact– Trianni, Inc.
David Meininger
Chief Business Officer
1.866.674.9314
[e-mail]

Mandy Boyd
Director of Marketing
1.415.231.0256 [o]
1.866.674.9314
[e-mail]

View original content with multimedia:http://www.prnewswire.com/news-releases/trianni-and-juno-therapeutics-sign-licensing-agreement-for-use-of-trianni-transgenic-mouse-platform-300538676.html

SOURCE Trianni, Inc.

Copyright 2017 PR Newswire